Phenotypes associated with this allele

• Allele Symbol: Trp53^tm1Glo
• Allele Name: targeted mutation 1, Guillermina Lozano
• Allele ID: MGI:2386273
• Summary: 12 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Trp53^tm1Glo/Trp53^tm1Glo	involves: 129S7/SvEvBrd * C57BL/6	MGI:3814408
hm2	Trp53^tm1Glo/Trp53^tm1Glo	involves: 129S7/SvEvBrd * C57BL/6J	MGI:5003354
ht3	Trp53^tm1Glo/Trp53^+	involves: 129S7/SvEvBrd	MGI:3814437
ht4	Trp53^tm1Glo/Trp53^+	involves: 129S7/SvEvBrd * C57BL/6	MGI:3814412
ht5	Trp53^tm1Glo/Trp53^+	involves: 129S7/SvEvBrd * C57BL/6J	MGI:5003355
ht6	Trp53^tm1Glo/Trp53^tm4Glo	involves: 129S7/SvEvBrd * C57BL/6	MGI:5000505
cn7	Trp53^tm1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc/0	involves: 129S7/SvEvBrd * C57BL/6 * CBA	MGI:5000506
cx8	Cops6^Gt(RRI087)Byg/Cops6^+ Trp53^tm1Glo/Trp53^+	involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J	MGI:5003356
cx9	Cops6^Gt(RRI087)Byg/Cops6^Gt(RRI087)Byg Trp53^tm1Glo/Trp53^tm1Glo	involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J	MGI:5003353
cx10	Kras^tm2Tyj/Kras^+ Trp53^tm1Glo/Trp53^+	involves: 129S2/SvPas * 129S7/SvEvBrd	MGI:3814436
cx11	Mdm2^tm1Glo/Mdm2^tm1Glo Trp53^tm1Glo/Trp53^tm1Glo	involves: 129S7/SvEvBrd * C57BL/6	MGI:5000503
cx12	Mdm2^tm1Glo/Mdm2^tm1Glo Trp53^tm1Glo/Trp53^tm4Glo	involves: 129S7/SvEvBrd * C57BL/6	MGI:5000502

Genotype
MGI:3814408

hm1

• Allelic Composition: Trp53^tm1Glo/Trp53^tm1Glo
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased tumor-free survival time ( J:61683 )

• mice die by 40 weeks of age associated with early onset spontaneous tumor formation

neoplasm

increased tumor incidence ( J:61683 )

increased T cell derived lymphoma incidence ( J:61683 )

• in 75% of mice

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:61683 )

• in 75% of mice

hematopoietic system

increased T cell derived lymphoma incidence ( J:61683 )

• in 75% of mice

immune system

increased T cell derived lymphoma incidence ( J:61683 )

• in 75% of mice

Genotype
MGI:5003354

hm2

• Allelic Composition: Trp53^tm1Glo/Trp53^tm1Glo
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6J

immune system

decreased thymocyte apoptosis ( J:172038 )

• gamma-irradiation-induced

hematopoietic system

decreased thymocyte apoptosis ( J:172038 )

• gamma-irradiation-induced

cellular

decreased thymocyte apoptosis ( J:172038 )

• gamma-irradiation-induced

endocrine/exocrine glands

decreased thymocyte apoptosis ( J:172038 )

• gamma-irradiation-induced

Genotype
MGI:3814437

ht3

• Allelic Composition: Trp53^tm1Glo/Trp53⁺
• Genetic Background: involves: 129S7/SvEvBrd

neoplasm

increased tumor incidence ( J:129627 )

• mice develop adenocarcinomas, adenomas, lymphomas, osteosarcoma, and squamous carcinomas

increased lymphoma incidence ( J:129627 )

increased carcinoma incidence ( J:129627 )

• including lung adenocarcinomas

increased squamous cell carcinoma incidence ( J:129627 )

increased sarcoma incidence ( J:129627 )

increased osteosarcoma incidence ( J:129627 )

skeleton

increased osteosarcoma incidence ( J:129627 )

Genotype
MGI:3814412

ht4

• Allelic Composition: Trp53^tm1Glo/Trp53⁺
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

mortality/aging

decreased tumor-free survival time ( J:61683 )

• premature death is associated with early onset spontaneous tumor formation

neoplasm

increased metastatic potential ( J:61683 )

• mice develop highly metastatic tumors such as osteosarcomas and carcinomas with 17 of 51 mice exhibiting metastasis nodules in the lung, liver or both

• 69% of osteosarcomas metastasize whereas osteosarcomas in mice heterozygous for a Trp53 null allele rarely metastasize

• 40% of adenocarcinomas and squamous cell carcinomas metastasize

• however, fibrosarcomas do not exhibit metastasis

increased tumor incidence ( J:61683 )

• mice exhibit an increased rate of tumorigenesis and develop osteosarcomas, fibrosarcomas, angiosarcomas, lyposarcomas, adenocarcinomas, hepatocellular carcinomas, poorly differentiated carcinomas, squamous cell carcinomas, lymphoma and adenoma

• however, tumorigenesis is rarely accompanied by loss of heterozygosity

increased lymphoma incidence ( J:61683 )

• 16% of mice develop lymphomas compared to 25% and 32% of mice heterozygous for one of two Trp53 null allele

increased carcinoma incidence ( J:61683 )

• 29% of mice develop carcinomas compared to only 10% of mice heterozygous for a Trp53 null allele

increased squamous cell carcinoma incidence ( J:61683 )

increased sarcoma incidence ( J:61683 )

• in 54% of mice

increased fibrosarcoma incidence ( J:61683 )

increased hemangiosarcoma incidence ( J:61683 )

increased osteosarcoma incidence ( J:61683 )

skeleton

increased osteosarcoma incidence ( J:61683 )

Genotype
MGI:5003355

ht5

• Allelic Composition: Trp53^tm1Glo/Trp53⁺
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6J

neoplasm

increased incidence of tumors by ionizing radiation induction ( J:172038 )

Genotype
MGI:5000505

ht6

• Allelic Composition: Trp53^tm1Glo/Trp53^tm4Glo
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

mortality/aging

decreased tumor-free survival time ( J:171821 )

• medial survival is 251 days due to tumor development

neoplasm

abnormal tumor morphology ( J:171821 )

• tumors exhibit interstitial inflammatory cells unlike in tumors from Trp53^tm1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc mice

increased lipoma incidence ( J:171821 )

• in 2% of mice

increased lymphoma incidence ( J:171821 )

• in 34% of mice (including T cell, diffuse, anaplastic, and lymph node)

increased T cell derived lymphoma incidence ( J:171821 )

increased adenocarcinoma incidence ( J:171821 )

• in 2% of mice

increased spindle cell carcinoma incidence ( J:171821 )

increased sarcoma incidence ( J:171821 )

• in 61% of mice (including angiosarcoma, spindle-cell, giant-cell, and anaplastic)

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:171821 )

hematopoietic system

increased T cell derived lymphoma incidence ( J:171821 )

immune system

increased T cell derived lymphoma incidence ( J:171821 )

Genotype
MGI:5000506

cn7

• Allelic Composition: Trp53^tm1Glo/Trp53^tm4Glo; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * CBA

mortality/aging

extended life span ( J:171821 )

• tamoxifen-treated mice survive longer than Trp53^tm1Glo/Trp53^tm4Glo mice

neoplasm

abnormal tumor pathology ( J:171821 )

• tamoxifen-treated lymphomas exhibit decreased apoptosis response compared with tumors from Trp53^tm3.1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc mice

• tamoxifen-treated tumors exhibit decreased cell proliferation compared with control samples

• angiosarcomas treated with tamoxifen exhibit increased senescence compared with tamoxifen-treated angiosarcomas from Trp53^tm3.1Glo/Trp53^tm4Glo Tg(CAG-cre/Esr1*)5Amc mice

• tamoxifen-treatment induces apoptosis and senescence in giant-cell sarcoma

tumor regression ( J:171821 )

• in tamoxifen-treated mice

Genotype
MGI:5003356

cx8

• Allelic Composition: Cops6^{Gt(RRI087)Byg}/Cops6⁺; Trp53^tm1Glo/Trp53⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J

neoplasm

increased incidence of tumors by ionizing radiation induction ( J:172038 )

• mice exhibit a spectrum of gamma-irradiation-induced tumors intermediate to in Trp53^tm1Glo heterozygotes and Cops6^{Gt(RRI087)Byg} heterozygotes

Genotype
MGI:5003353

cx9

• Allelic Composition: Cops6^{Gt(RRI087)Byg}/Cops6^{Gt(RRI087)Byg}; Trp53^tm1Glo/Trp53^tm1Glo
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J

The embryonic lethality of Cops6^{Gt(RRI087)Byg}/Cops6^{Gt(RRI087)Byg} mice can be partially rescued by concomitant loss of Trp53

mortality/aging

prenatal lethality, complete penetrance ( J:172038 )

• no mice are detected at birth

• however, mice were identified at E8.5 to E10.5 indicating a partial rescue

embryo

embryonic growth retardation ( J:172038 )

• at E9.5

decreased embryo size ( J:172038 )

• at E9.5

growth/size/body

embryonic growth retardation ( J:172038 )

• at E9.5

decreased embryo size ( J:172038 )

• at E9.5

Genotype
MGI:3814436

cx10

• Allelic Composition: Kras^tm2Tyj/Kras⁺; Trp53^tm1Glo/Trp53⁺
• Genetic Background: involves: 129S2/SvPas * 129S7/SvEvBrd

mortality/aging

premature death ( J:129627 )

• average lifespan is 266 days with female mice exhibiting shorter lifespans than male mice

neoplasm

increased metastatic potential ( J:129627 )

• lung adenocarcinomas and mesothelioma are highly invasive and metastatic with metastatic lesions observed in the lymph nodes and liver

• 19 of 52 mice with lung adenocarcinomas exhibit metastasis compared to only 2 of 44 Kras^tm2Tyj heterozygotes

abnormal tumor morphology ( J:129627 )

• 81.8% of mice with end-stage lung adenocarcinomas exhibit loss of heterozygosity of the Trp53 wild-type allele

increased tumor incidence ( J:129627 )

• mice develop adenocarcinomas, adenomas, lymphomas, mesotheliomas, angiosarcomas, fibrosarcomas, pancreatic carcinomas, squamous carcinomas, and papillomas

increased lung adenoma incidence ( J:129627 )

• 52 of 56 mice develop atypical adenamatous hyperplasia, adenomas and adenocarcinomas

• most mice develop multiple large or diffuse adenocarcinomas that have glandular phenotypes or are poorly differentiated

increased lymphoma incidence ( J:129627 )

• some mice develop lung lymphomas

increased squamous cell carcinoma incidence ( J:129627 )

increased fibrosarcoma incidence ( J:129627 )

increased hemangiosarcoma incidence ( J:129627 )

increased mesothelioma incidence ( J:129627 )

• 13 of 56 mice develop mesothelioma 6 of which are peritoneal mesotheliomas

increased papilloma incidence ( J:129627 )

respiratory system

increased lung adenoma incidence ( J:129627 )

• 52 of 56 mice develop atypical adenamatous hyperplasia, adenomas and adenocarcinomas

• most mice develop multiple large or diffuse adenocarcinomas that have glandular phenotypes or are poorly differentiated

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:129627

Genotype
MGI:5000503

cx11

• Allelic Composition: Mdm2^tm1Glo/Mdm2^tm1Glo; Trp53^tm1Glo/Trp53^tm1Glo
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

mortality/aging

embryonic lethality, complete penetrance ( J:171821 )

• as in Mdm2^tm1Glo homozygotes

Genotype
MGI:5000502

cx12

• Allelic Composition: Mdm2^tm1Glo/Mdm2^tm1Glo; Trp53^tm1Glo/Trp53^tm4Glo
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

mortality/aging

postnatal lethality, complete penetrance ( J:171821 )

growth/size/body

decreased body size ( J:171821 )

behavior/neurological

decreased locomotor activity ( J:171821 )

• less mobile